We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
+1.17%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$406M
AUM Growth
+$71.8M
Cap. Flow
+$62M
Cap. Flow %
15.25%
Top 10 Hldgs %
55.4%
Holding
62
New
16
Increased
17
Reduced
12
Closed
17

Top Buys

Rank Stock Value
1
MCK icon
McKesson
MCK
+$19.9M
2
ABCL icon
AbCellera Biologics
ABCL
+$18.6M
3
DXCM icon
DexCom
DXCM
+$9.09M
4
JANX icon
Janux Therapeutics
JANX
+$8.92M
5
BBIO icon
BridgeBio Pharma
BBIO
+$7.53M

Top Sells

Rank Stock Value
1
KELYA icon
Kelly Services Class A
KELYA
+$10.5M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$8.74M
3
ALKS icon
Alkermes
ALKS
+$6.63M
4
KIDS icon
OrthoPediatrics
KIDS
+$5.76M
5
OPCH icon
Option Care Health
OPCH
+$5.68M

Sector Composition

Rank Sector Weight
1 Healthcare 94.39%
2 Miscellaneous 2.95%
3 Industrials 2.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADCT icon
1
ADC Therapeutics
ADCT
$146M
$30.4M 7.47%
9,636,237
+66,237
+0.7% +$209K
LKFT
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$29.6M 7.29%
1,028,843
-321,137
-24% -$8.74M
BBIO icon
3
BridgeBio Pharma
BBIO
$15B
$27.7M 6.81%
1,086,810
+286,810
+36% +$7.53M
ABCL icon
4
AbCellera Biologics
ABCL
$3.68B
$23.6M 5.81%
9,079,539
+6,726,906
+286% +$18.6M
MGTX icon
5
MeiraGTx Holdings
MGTX
$1.33B
$20.4M 5.03%
4,900,570
+547,870
+13% +$2.37M
ROIV icon
6
Roivant Sciences
ROIV
$25.1B
$19.9M 4.89%
1,721,512
-278,488
-14% -$3.17M
STTK icon
7
Shattuck Labs
STTK
$707M
$19.8M 4.88%
5,678,726
+1,008,726
+22% +$3.76M
MIRM icon
8
Mirum Pharmaceuticals
MIRM
$5.94B
$18.2M 4.47%
465,825
+151,025
+48% +$6.02M
ZBH icon
9
Zimmer Biomet
ZBH
$19.2B
$17.9M 4.4%
165,602
-4,398
-3% -$480K
MCK icon
10
McKesson
MCK
$104B
$17.7M 4.36%
+35,822
New +$19.9M
KURA icon
11
Kura Oncology
KURA
$1.13B
$13.8M 3.39%
705,109
+75,209
+12% +$1.52M
SDGR icon
12
Schrodinger
SDGR
$1.47B
$13M 3.2%
700,000
+330,739
+90% +$6.79M
ZYME icon
13
Zymeworks
ZYME
$2.02B
$11.5M 2.83%
917,599
-262,401
-22% -$2.86M
ACCD
14
DELISTED
Accolade Inc
ACCD
$10.8M 2.65%
2,801,598
+1,312,073
+88% +$5.14M
DXCM icon
15
DexCom
DXCM
$34.3B
$10.7M 2.64%
160,000
+110,683
+224% +$9.09M
SNDX icon
16
Syndax Pharmaceuticals
SNDX
$1.74B
$10.7M 2.62%
554,103
+2,559
+0.5% +$52.9K
IMVT icon
17
Immunovant
IMVT
$8.51B
$10.5M 2.6%
370,000
+45,000
+14% +$1.33M
CYTK icon
18
Cytokinetics
CYTK
$10B
$10.2M 2.5%
192,700
-37,300
-16% -$2.08M
JANX icon
19
Janux Therapeutics
JANX
$1.1B
$9.31M 2.29%
+205,000
New +$8.92M
PRTA icon
20
Prothena Corp
PRTA
$479M
$8.09M 1.99%
483,467
+196,541
+68% +$4.23M
NBIX icon
21
Neurocrine Biosciences
NBIX
$15.7B
$7.14M 1.76%
62,000
+35,000
+130% +$4.8M
OEF icon
22
PUT
iShares S&P 100 ETF
OEF
$20.5B
$6.41M 1.58%
+29,000
New +$7.75M
ERAS icon
23
Erasca
ERAS
$6.31B
$5.42M 1.33%
1,984,010
-765,990
-28% -$2.16M
HAE icon
24
Haemonetics
HAE
$4.73B
$5.22M 1.29%
+65,000
New +$5.25M
LIVN icon
25
LivaNova
LIVN
$4.43B
$4.73M 1.16%
+90,000
New +$4.46M
1
2 3

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q3 2024 Portfolio in Review

As of Q3 2024, Prosight Management held 62 positions worth $406M, up 21% from $335M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Prosight Management deployed $62M of net new capital in Q3 2024, opening 16 new positions and adding to 17 existing holdings. Its largest new stake was McKesson: 35,822 shares worth $17.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Lakefront Biotherapeutics American Depositary Shares, an estimated $8.74M trimmed.

  • Prosight Management's largest Q3 2024 buy was McKesson: 35,822 shares worth $17.7M.
  • Prosight Management added most to AbCellera Biologics in Q3 2024, an estimated $18.6M increase.
  • Prosight Management's biggest Q3 2024 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $8.74M.
  • Prosight Management fully exited Kelly Services Class A in Q3 2024, selling an estimated $10.5M.
  • Prosight Management's ten largest holdings make up 55% of its $406M portfolio in Q3 2024.
  • Prosight Management opened 16 new positions and closed 17 in Q3 2024.
  • Prosight Management's portfolio value rose 21% quarter-over-quarter to $406M.

Based on Prosight Management's 13F filing for Q3 2024, filed 14 Nov 2024.